Modulating both inhibitory and stimulatory immune pathways may also be a promising approach as dual CTLA-4 blockade and ICOS stimulation provides improved antitumor control against preclinical murine melanoma and prostate cancer.61 This evidence concerns the gene CTLA4 and melanoma.